PORTOLA VALLEY, Calif., Jan. 12 /PRNewswire/ -- Spectros announced today that the T-Stat(R) Tissue Oximeter sensor line will be expanded to include the new Continuum(TM) Cerebral Sensor line upon receipt of FDA marketing approval anticipated in 2010.
“The expansion of the T-Stat product line to include cerebral sensors furthers the already market-leading accuracy and success of the T-Stat into cerebral oximetry monitoring,” notes Elizabeth van Thillo, Director of Marketing. “We currently have additional clinical studies at multiple clinical centers and will continue to demonstrate the efficacy of the T-Stat with the Continuum sensor line to reduce hospitalization costs and improve patient outcome in high-risk populations with early diagnosis.”
Spectros also develops molecular diagnostic tools for breast and prostate cancer, currently in phase I/II clinical trials supported by the National Cancer Institute. Spectros is a venture-supported private concern and markets its products in the U.S. and internationally. T-Stat competes in the oximetry marketplace with devices from Somanetics and CAS Medical.
For further information, visit www.spectros.com
CONTACT: Ms. Elizabeth van Thillo of Spectros, +1-650-529-2865
info@spectros.com
Web site: http://www.spectros.com/
